Clinical trial
Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or…
NCT00123929 · Hospital San Carlos, Madrid, Other · Completed
Key facts
| NCT number | NCT00123929 |
|---|---|
| Title | Genetic Expression and Prediction of Response to Neoadjuvant Docetaxel or Doxorubicin in Locally Advanced Breast Cancer |
| Official title | Patterns of Genetic Expression Associated to Sensibility to Doxorubicin Versus Docetaxel as Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer |
| Lead sponsor | Hospital San Carlos, Madrid, Other |
| Collaborators | UNC Lineberger Comprehensive Cancer Center |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, doxorubicin |
| Enrollment | 250 |
| Start date | Jan 1, 2005 |
| Primary completion | May 1, 2009 |
| Completion | May 1, 2009 |
| First posted | Jul 26, 2005 |
| Last update posted | Aug 6, 2009 |
| Countries | Spain |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: